Sculier J P, Paesmans M, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Schmerber J, Giner V, Berchier M C, Mommen P, Sergysels R, Klastersky J
Institut Jules Bordet, Bruxelles.
Rev Mal Respir. 1997 Dec;14(6):445-9.
The European Lung Cancer Working Party has investigated prognostic factors for response, overall survival, long term survival in a population with advanced non small cell lung cancer registered in a clinical trial evaluating platinum derivatives-containing chemotherapy regimens. Various factors have been identified in multivariate analyses and were classified using RECPAM methodology. In addition to the clinical factors such as disease extent and performance status were shown, as significant predictors, rarely studied biological factors like pretherapeutic leucocyte and polynuclear levels. The obtention of an objective response to chemotherapy appeared to be a major prognostic factor for further survival.
欧洲肺癌工作组在一项评估含铂衍生物化疗方案的临床试验所登记的晚期非小细胞肺癌患者群体中,研究了反应、总生存期、长期生存的预后因素。在多变量分析中已确定了各种因素,并使用RECPAM方法进行了分类。除了疾病范围和体能状态等临床因素被证明是显著预测因素外,治疗前白细胞和多核细胞水平等很少研究的生物学因素也是如此。化疗获得客观反应似乎是进一步生存的主要预后因素。